WO2008083228A3 - Compositions and methods for treating inflammation and auto-immune diseases - Google Patents

Compositions and methods for treating inflammation and auto-immune diseases Download PDF

Info

Publication number
WO2008083228A3
WO2008083228A3 PCT/US2007/088960 US2007088960W WO2008083228A3 WO 2008083228 A3 WO2008083228 A3 WO 2008083228A3 US 2007088960 W US2007088960 W US 2007088960W WO 2008083228 A3 WO2008083228 A3 WO 2008083228A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disorders
activity
compositions
auto
Prior art date
Application number
PCT/US2007/088960
Other languages
French (fr)
Other versions
WO2008083228A2 (en
Inventor
Lieping Chen
Original Assignee
Univ Johns Hopkins
Lieping Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Lieping Chen filed Critical Univ Johns Hopkins
Priority to EP20070866065 priority Critical patent/EP2124998B8/en
Priority to AU2007339762A priority patent/AU2007339762B2/en
Priority to CA002673659A priority patent/CA2673659A1/en
Priority to JP2009544267A priority patent/JP5481199B2/en
Publication of WO2008083228A2 publication Critical patent/WO2008083228A2/en
Publication of WO2008083228A3 publication Critical patent/WO2008083228A3/en
Priority to HK10105325.3A priority patent/HK1139070A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3413—Diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions containing soluble B7-H4 (sH4) antagonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders are provided. Soluble H4 has been discovered to interfere with B7-H4 activity including B7-H4's activity as an inhibitor of T cell immunity. Thus, interference of sH4 biological activity is an effective method to restore B7-H4 activity and thereby provide an effective method for treating inflammatory diseases or disorders including autoimmune diseases or disorders.
PCT/US2007/088960 2006-12-27 2007-12-27 Compositions and methods for treating inflammation and auto-immune diseases WO2008083228A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20070866065 EP2124998B8 (en) 2006-12-27 2007-12-27 Methods for detecting inflammation and auto-immune diseases
AU2007339762A AU2007339762B2 (en) 2006-12-27 2007-12-27 Compositions and methods for treating inflammation and auto-immune diseases
CA002673659A CA2673659A1 (en) 2006-12-27 2007-12-27 Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
JP2009544267A JP5481199B2 (en) 2006-12-27 2007-12-27 Compositions and methods for treating inflammation and autoimmune diseases
HK10105325.3A HK1139070A1 (en) 2006-12-27 2010-05-31 Methods for detecting inflammation and auto-immune diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87731906P 2006-12-27 2006-12-27
US60/877,319 2006-12-27
US94974207P 2007-07-13 2007-07-13
US60/949,742 2007-07-13

Publications (2)

Publication Number Publication Date
WO2008083228A2 WO2008083228A2 (en) 2008-07-10
WO2008083228A3 true WO2008083228A3 (en) 2008-11-06

Family

ID=39521467

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/088960 WO2008083228A2 (en) 2006-12-27 2007-12-27 Compositions and methods for treating inflammation and auto-immune diseases
PCT/US2007/088979 WO2008083239A2 (en) 2006-12-27 2007-12-27 Compositions and methods for stimulating an immune response

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088979 WO2008083239A2 (en) 2006-12-27 2007-12-27 Compositions and methods for stimulating an immune response

Country Status (7)

Country Link
US (4) US7931896B2 (en)
EP (3) EP2124998B8 (en)
JP (4) JP2011502954A (en)
AU (2) AU2007339762B2 (en)
CA (2) CA2673659A1 (en)
HK (2) HK1139070A1 (en)
WO (2) WO2008083228A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167206B1 (en) * 1984-06-22 1991-10-23 Mizusawa Industrial Chemicals Ltd. Synthetic fraipontite and process for preparation thereof
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
KR101429013B1 (en) * 2007-07-02 2014-08-11 삼성전자주식회사 Method for producing of conductive transfer roller, transfer roller thereof and image forming apparatus comprising the same
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
US20110200600A1 (en) * 2008-09-10 2011-08-18 Indiana University Research And Technology Corporation Diagnosis and prognosis of immune disorders using stat4 expression
EP2464661B1 (en) * 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
CA2772199A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
WO2012145568A1 (en) * 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
CA2894879A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EP2997373A1 (en) 2013-05-17 2016-03-23 MedImmune, LLC Receptors for b7-h4
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
JP2019500892A (en) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Antibodies that specifically bind to TIM-3 and uses thereof
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
KR20200112913A (en) 2018-01-23 2020-10-05 넥스트큐어 인코포레이티드 B7-H4 antibody and method of use
SG11202008105RA (en) 2018-03-02 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019217657A1 (en) * 2018-05-10 2019-11-14 TympoBio, Inc. Compositions and methods for treating autoimmune inner ear disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840513A (en) * 1968-04-19 1974-10-08 Microbial Chem Res Found Therapeutically useful compound,leupeptins,and processes for the preparation thereof
US20020168762A1 (en) * 2000-07-27 2002-11-14 Lieping Chen B7-H3 and B7-H4, novel immunoregulatory molecules
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
WO2004000221A2 (en) * 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US20040229795A1 (en) * 1999-08-13 2004-11-18 Aventis Behring Gmbh Use of antithrombin III for the prophylaxis and therapy of diseases
US20050163772A1 (en) * 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36107A (en) * 1862-08-05 Improvement in
US202587A (en) * 1878-04-16 Improvement in door-hangers
US12758A (en) * 1855-04-24 chane
JPS6050743B2 (en) * 1976-06-02 1985-11-09 旭光学工業株式会社 Apatite sintered body and its manufacturing method
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
CH652145A5 (en) * 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0279582A3 (en) * 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5278056A (en) * 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US4891719A (en) * 1988-10-03 1990-01-02 Datatape Incorporated Fast closure method for a data signal channel
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (en) * 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2082951C (en) * 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (en) * 1991-05-15 2000-03-09 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
KR0163798B1 (en) 1991-07-03 1999-01-15 나가따 마사오 Thermoplastic polyarethane elastomer, method and device for manufacture thereof, and elastic fiber made therefrom
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932224B (en) 1992-03-30 1994-09-29 American Home Prod Rapamycin formulation for IV injection
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
JP3720353B2 (en) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
DE4301681C1 (en) * 1993-01-22 1994-10-20 Deutsche Aerospace Airbus Pipe branch between an air line and an air shower
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
DE69435171D1 (en) 1993-09-14 2009-01-08 Pharmexa Inc PAN DR BINDEPROTEINS FOR INCREASING THE IMMUNE RESPONSE
WO1995012972A1 (en) 1993-11-08 1995-05-18 Cressy, Wayne, Malcolm Head restraining device
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859959B1 (en) 1995-11-10 2003-08-06 ELAN CORPORATION, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE69707033T2 (en) * 1996-03-05 2002-02-14 Hitachi Ltd Process for the treatment of gases containing organohalogen compositions
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6982323B1 (en) * 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
JP2002523760A (en) 1998-09-02 2002-07-30 ダイアデクスアス・インコーポレーテッド Novel methods for diagnosing, monitoring, staging, imaging and treating various cancers
US6962980B2 (en) * 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001001137A1 (en) * 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
AU2001273194A1 (en) * 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
US7975021B2 (en) * 2000-10-23 2011-07-05 Clearplay, Inc. Method and user interface for downloading audio and video content filters to a media player
US6828112B2 (en) * 2001-01-04 2004-12-07 Myriad Genetics, Inc. Method of detecting protein-protein interactions
RU2297245C2 (en) * 2001-02-19 2007-04-20 Мерк Патент Гмбх Modified anti-egfr antibodies with reduced ammonogenicity
US20050215727A1 (en) * 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
IL150013A (en) * 2002-06-04 2007-06-17 Gil Hecht Rotary cutting tool
US7449300B2 (en) * 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
US7334413B2 (en) * 2004-05-07 2008-02-26 Rosemount Aerospace Inc. Apparatus, system and method for observing combustion conditions in a gas turbine engine
DE102004060403A1 (en) * 2004-12-14 2006-07-06 Trützschler GmbH & Co KG Device in the spinning preparation for feeding a plurality of filling shafts, in particular mixers, with fiber material
US7694100B2 (en) * 2004-12-20 2010-04-06 Intel Corporation Managing system memory resident device management queues
EP1863532A1 (en) * 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
BRPI0611766A2 (en) * 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc methods and compositions for the treatment of persistent infections and cancer by inhibition of the programmed cell death pathway
US20070039150A1 (en) * 2005-08-08 2007-02-22 Thomas David L Convertible furniture system comprised of modular convertible box frames and methods of forming various furniture configurations therefrom
KR100779170B1 (en) * 2005-08-16 2007-11-23 학교법인 포항공과대학교 Butt coupling method with photonic quantum ring hole emitter
JP4730263B2 (en) * 2005-09-21 2011-07-20 富士ゼロックス株式会社 Image processing device maintenance system
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
CN101399708B (en) * 2007-09-28 2012-04-04 华为技术有限公司 Method and device for establishing network performance model
JP2011503104A (en) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー Immunomodulatory compounds and related compositions and methods
CA2772199A1 (en) * 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840513A (en) * 1968-04-19 1974-10-08 Microbial Chem Res Found Therapeutically useful compound,leupeptins,and processes for the preparation thereof
US20040229795A1 (en) * 1999-08-13 2004-11-18 Aventis Behring Gmbh Use of antithrombin III for the prophylaxis and therapy of diseases
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
US20020168762A1 (en) * 2000-07-27 2002-11-14 Lieping Chen B7-H3 and B7-H4, novel immunoregulatory molecules
WO2004000221A2 (en) * 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
US20040175380A1 (en) * 2002-06-20 2004-09-09 Allison James P. Compositions and methods for modulating lymphocyte activity
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US20050163772A1 (en) * 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Plasmapheresis in severe autoimmune hepatitis - N Zakaria, P Harrison, I McFarlane, J Devlin, King's College Hospital, London United Kingdom", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 34, no. 4, 1 October 2001 (2001-10-01), pages A529, XP004716960, ISSN: 0270-9139 *
DAU P C: "The fundamental basis for therapeutic plasmapheresis in autoimmune diseases", TRANSFUSION SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 17, no. 2, 1 June 1996 (1996-06-01), pages 235 - 244, XP004568785, ISSN: 0955-3886 *
MALCHESKY P S ET AL: "ARE SELECTIVE MACROMOLECULE REMOVAL PLASMAPHERESIS SYSTEMS USEFUL FOR AUTOIMMUNE DISEASES OR HYPERLIPIDEMIA?", ASAIO JOURNAL, LIPPINCOTT WILLIAMS & WILKINS / ASAIO, HAGERSTOWN, MD, US, vol. 39, no. 4, 1 October 1993 (1993-10-01), pages 868 - 872, XP000423348, ISSN: 1058-2916 *
MEDINA C ET AL: "THERAPEUTIC EFFECT OF PHENANTROLINE IN TWO RAT MODELS OF INFLAMMATORY BOWEL DISEASE", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, XX, XX, vol. 36, no. 12, 1 January 2001 (2001-01-01), pages 1314 - 1319, XP008067562, ISSN: 0036-5521 *
OU DAWEI ET AL: "B7-H4.Ig inhibits human beta-cell destruction mediated by beta cell-specific cytotoxic T cells derived from patients with type 1 diabetes", DIABETES, NEW YORK, NY, US, vol. 54, no. Suppl. 1, 14 June 2005 (2005-06-14), pages A311, XP009101950, ISSN: 0012-1797 *
SICA GABRIEL L ET AL: "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.", IMMUNITY, vol. 18, no. 6, June 2003 (2003-06-01), pages 849 - 861, XP002485368, ISSN: 1074-7613 *

Also Published As

Publication number Publication date
JP2013155199A (en) 2013-08-15
AU2007339773A1 (en) 2008-07-10
EP2586458A1 (en) 2013-05-01
CA2673752A1 (en) 2008-07-10
JP2011502954A (en) 2011-01-27
JP2010530354A (en) 2010-09-09
JP5926701B2 (en) 2016-05-25
JP2016035474A (en) 2016-03-17
EP2109455A2 (en) 2009-10-21
AU2007339762A1 (en) 2008-07-10
EP2124998B8 (en) 2015-05-06
AU2007339762B2 (en) 2011-03-31
CA2673659A1 (en) 2008-07-10
US20080160036A1 (en) 2008-07-03
EP2124998B1 (en) 2015-02-18
US20110171207A1 (en) 2011-07-14
EP2124998A2 (en) 2009-12-02
US7931896B2 (en) 2011-04-26
JP5481199B2 (en) 2014-04-23
EP2586458B1 (en) 2016-08-24
WO2008083228A2 (en) 2008-07-10
US20110195073A1 (en) 2011-08-11
WO2008083239A2 (en) 2008-07-10
HK1139070A1 (en) 2010-09-10
WO2008083239A3 (en) 2008-08-28
HK1184697A1 (en) 2014-01-30
AU2007339773B2 (en) 2011-03-10
US20080206235A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008083228A3 (en) Compositions and methods for treating inflammation and auto-immune diseases
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
WO2008045664A3 (en) Heterocyclic pde4 inhibitors as antiinflammatory agents
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
MY157944A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associat ed with angiogenesis
EP2687220A3 (en) Treatment of inflammatory diseases using placental stem cells
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
NZ596244A (en) Treatment of neurodegenerative diseases
WO2002026727A3 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
MX2013012151A (en) Method of inhibiting harmful microorganisms and barrier-forming composition therefor.
WO2008075231A3 (en) Diaper rash composition and method
WO2006060737A3 (en) Mitotic kinesin inhibitors
WO2006053555A3 (en) Pyrazol-3-one and/or pyridazin-3-one derivatives used as inhibitors of lysyl oxidase
WO2009130615A3 (en) Use of deuterium oxide as an elastase inhibitor
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2005065668A3 (en) Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
WO2008045663A3 (en) Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
WO2007015175A3 (en) Use of pp-1 inhibitors to prevent missplicing events
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2009009114A3 (en) Compositions and methods for treating and diagnosing cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866065

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2673659

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009544267

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007339762

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007866065

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007339762

Country of ref document: AU

Date of ref document: 20071227

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)